GLP-1 Medications in India: A Complete 2026 Guide

In October 2026, India has three GLP-1 medicines on sale for weight management: semaglutide (Ozempic, Wegovy and about 35 generic brands, from roughly ₹1,300 a month), tirzepatide (Mounjaro and Yurpeak, ₹13,125 to ₹25,781 a month at MRP), and oral semaglutide tablets. All of them are prescription-only, and since March 2026 regulators actively police that rule. This guide covers what each costs, what it is approved for, how to get a legitimate prescription, and what is coming next.

GLP-1 medicines in India, October 2026

The big 2026 story is the collapse in semaglutide pricing. A September 2026 review in Diabetes Care by the Madras Diabetes Research Foundation found typical monthly prices fell from ₹11,000 to ₹16,409 before the patent expiry to ₹2,000 to ₹3,500 after it, and unit sales rose about tenfold in the first six months. Tirzepatide stayed premium because it has no generic, yet demand kept growing: Mounjaro sold ₹112 crore in August 2026 alone, more than any other GLP-1 in India.

Semaglutide or tirzepatide?

Both work on the GLP-1 hormone pathway to reduce appetite and slow digestion; tirzepatide also acts on a second hormone, GIP. In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. Semaglutide is the cheaper and more studied place to start for most first-time patients; tirzepatide makes sense with more weight to lose, a higher starting BMI, or a poor response to semaglutide. Our full comparison is semaglutide vs tirzepatide in India.

The rules in 2026: what regulators now enforce

• Prescription only. CDSCO's advisory of 10 March 2026 says GLP-1 medicines must only be prescribed by registered medical practitioners and sold against a prescription. Selling or buying without one is not a grey area.
• No advertising to the public. The same advisory bars public-facing promotion and surrogate advertising of these drugs. In May 2026 CDSCO asked every state and union territory to monitor it.
• Enforcement is real. On 14 August 2026, Telangana's drug regulator raided 43 pharmacies and issued show-cause notices for selling semaglutide and tirzepatide without specialist prescriptions, bills or records.
• Who prescribes. Some state advisories expect a specialist, usually an endocrinologist or internal medicine physician, and CDSCO's expert panel attached the same condition to orforglipron. A doctor-led programme with those specialists on its bench sits well inside the rules.
• Counterfeits exist. In April 2026 Haryana regulators seized more than 260 fake Mounjaro pens that were being sold on an online B2B marketplace at a discount. Buy only from licensed pharmacies, against your own prescription.

How to get prescribed: the two routes

The traditional route: book a clinic appointment, wait for a slot, attend in person, get blood tests done separately, then collect a prescription and buy the medicine yourself. For a lot of working adults, the waiting and logistics are the reason they never start.

The ALTRcare route: a 2-minute online assessment, a free 15 to 20 minute video consultation with one of four named senior specialists (an endocrinologist, two internal medicine physicians and a diabetologist), and, only if it is clinically appropriate, a prescription and a supervised plan with the medicine delivered cold, monthly consultations, dose changes and side-effect support. Recent blood reports are usually enough; if your doctor needs new tests, they can be collected at home.

What is coming next

• Orforglipron (Foundayo), Eli Lilly's daily GLP-1 tablet. FDA-approved in April 2026. In June 2026 CDSCO's Subject Expert Committee recommended it for import and marketing in India, on condition it is sold only on an endocrinologist's or internal medicine specialist's prescription. On 2 October Lilly's CEO said the company is ready to launch as soon as Indian authorities approve; 2027 looks likely. No Indian price yet.
• The Wegovy pill (oral semaglutide 25 mg). Launched in the US in January 2026; Novo Nordisk plans first launches outside the US in the second half of 2026. Not approved in India yet.
• Wegovy 7.2 mg. A higher weekly dose approved by the US FDA in March 2026. No Indian plan announced.
• Retatrutide. Lilly's triple-hormone injection produced 28.3% average weight loss at 80 weeks in the TRIUMPH-1 trial (May 2026). It is investigational everywhere; Lilly plans to file with the FDA in early 2027. Anything sold as retatrutide in India today is unlicensed.
• Generic tirzepatide. Not in India; compound protection runs to 2036.

What to know before you start

• GLP-1s aren't steroids or crash diets. They are peptide medicines that work with your body's own appetite hormones.
• You'll experience reduced hunger, not starvation.
• Results last while you're on treatment; stopping abruptly without a plan often leads to regain.
• Most people tolerate them well, with mild, temporary stomach side effects in the first few weeks.
• Safety picture: in January 2026 the US FDA removed the suicidal-thoughts warning from the Wegovy, Saxenda and Zepbound labels after its review found no increased risk. Pancreatitis, gallbladder problems and a very rare eye condition (NAION) remain on the list your doctor checks.
• BMI is not the whole story for Indians. The 2025 Asian Indian obesity definition starts at a BMI of 23 with abdominal fat, and the August 2026 OSSI and Endocrine Society of India consensus says treatment should not rest on BMI alone.